If FDA ends up approving Addyi (flibanserin), it will be a sort of “make-up call,” IMO. I.e. the FDA probably should have approved PG’s Intrinsa ten years ago, but there was a lot of overblown discussion of the safety risks and PG eventually dropped the program. If there were (hypothetically) a head-to-head study of Intrinsa vs Addyi, I would be willing to bet that Intrinsa would prove to be more efficacious and probably safer too.
I think FSDD deserves to be treated as a real disorder, but Addyi is the wrong drug for the task.
News 
Market Data 
Discover 
